TMV-018 / Merck (MSD), Max Planck Institute - LARVOL DELTA

A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: Themis Bioscience GmbH; N=15 ➔ 0; Trial completion date: Dec 2023 ➔ Nov 2020; Initiation date: Jun 2020 ➔ Nov 2020; Not yet recruiting ➔ Withdrawn; Trial primary completion date: Dec 2021 ➔ Nov 2020

Clinical • Combination therapy • Enrollment change • IO Biomarker • Trial completion date • Trial initiation date • Trial primary completion date • Trial withdrawal • Gastrointestinal Cancer • Gastrointestinal Disorder • Oncology • Solid Tumor

A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract (clinicaltrials.gov) - P1; N=15; Not yet recruiting; Sponsor: Themis Bioscience GmbH; Phase classification: P1/2 ➔ P1; N=39 ➔ 15; Trial completion date: Dec 2024 ➔ Dec 2023; Trial primary completion date: Dec 2022 ➔ Dec 2021

Clinical • Combination therapy • Enrollment change • IO Biomarker • Phase classification • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Oncology • Solid Tumor